Article Versions Notes

Ozawa H, Haratake N, Nakashoji A, Daimon T, Bhattacharya A, Wang K, Shigeta K, Fushimi A, Fukuda K, Masugi Y, et al. MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer. Biomedicines. 2024; 12(7):1509. https://doi.org/10.3390/biomedicines12071509

Ozawa, Hiroki, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Keisuke Shigeta, Atsushi Fushimi, Kazumasa Fukuda, Yohei Masugi, and et al. 2024. "MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer" Biomedicines 12, no. 7: 1509. https://doi.org/10.3390/biomedicines12071509

Ozawa, H., Haratake, N., Nakashoji, A., Daimon, T., Bhattacharya, A., Wang, K., Shigeta, K., Fushimi, A., Fukuda, K., Masugi, Y., Yamaguchi, R., Kitago, M., Kawakubo, H., Kitagawa, Y., & Kufe, D. (2024). MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer. Biomedicines, 12(7), 1509. https://doi.org/10.3390/biomedicines12071509